Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|October 14, 2014
Showing Patients the Bigger Mobile Health Picture
Author(s)Guest Blogger
To understand just how far mobile and digital technology can truly influence progress in global healthcare, we first need to form the foundation of the discussion with a few rudimentary facts.
Advertisement
To understand just how far mobile and digital technology can truly influence progress in global healthcare, we first need to form the foundation of the discussion with a few rudimentary facts.
- Clinical research (“a branch of medical science in human beings”) is critical to healthcare.
- All patients are human beings.
- All stakeholders are current or potential patients.
- All stakeholders therefore have a vested interest in progression of healthcare.
Our current healthcare model is evolving, slowly but surely. How this progression is defined, and how mobile and digital technology can help to speed this along, is explored in this
Advertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
4
Closing the Pediatric Evidence Gap
5